Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the […]

Quantum BioPharma Gets FDA Green Light for First-in-Class MS Drug Targeting Myelin Repair

Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in multiple sclerosis treatment by targeting myelin repair, a mechanism never before tested in humans. The post Quantum BioPharma Gets FDA Green Light for First-in-Class MS Drug Targeting Myelin Repair appeared first on citybuzz.